IC
PRDS

Ikarian Capital’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Ikarian Capital’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-223,934
Closed -$687K – 174
2022
Q2 		$687K Sell
223,934
-100,000
-31% -$611K 0.13% 93
2022
Q1 		$2.34M Sell
323,934
-76,066
-19% -$748K 0.31% 60
2021
Q4 		$6.55M Buy
+400,000
New +$4.65M 0.98% 28

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Ikarian Capital's PRDS Position: Q3 2022 in Review

Ikarian Capital sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2022, closing a stake of 223,934 shares — an estimated $687K sold.

Ikarian Capital first reported a position in PRDS in Q4 2021 and held it in 3 quarters. The position peaked at $6.55M in Q4 2021. 68 funds tracked by Wall St. Rank hold PRDS as of Q3 2022.

  • Ikarian Capital reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 223,934 Pardes Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $687K.
  • Ikarian Capital first reported a position in Pardes Biosciences, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Ikarian Capital's Pardes Biosciences, Inc. Common Stock position peaked at $6.55M in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.